The Effect Effect of Empagliflozin on Oxidative Stress in Patients With Type 2 Diabetes (EMPOX)
Primary Purpose
Diabetes Mellitus, Type 2
Status
Completed
Phase
Phase 2
Locations
Denmark
Study Type
Interventional
Intervention
Empagliflozin
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 2 focused on measuring Empagliflozin, Oxidative stress, Oxidative nucleic acid modifications, 8-oxo-7,8-dihydro-2'-deoxyguanosine, 8-oxo-7,8-dihydroguanosine
Eligibility Criteria
Inclusion Criteria:
- Diagnosed with type 2 diabetes
- HbA1c: 6.5-9.0%
- Capable of understanding oral- and written information
- Caucasian
Exclusion Criteria:
- Estimated glomerular filtration rate (eGFR) < 60 mL/hour/1.73 m2
- Currently receiving insulin treatment
- Coronary artery bypass grafting, percutaneous coronary intervention, acute coronary syndrome, stroke, lung embolism, deep vein thrombosis, or transitory cerebral ischemia within 6 months
- Genital infection within 14 days
- Plasma alanine aminotransferase ≥3 times upper normal limit
- Treatment with sodium glucose cotransporter (SGLT) -2 inhibitor within 2 months
- Hyperglycaemic symptoms
- Psychiatric disorder
- Intolerance to empagliflozin or other agents relevant to study
- Non-compliant
Sites / Locations
- Center for Diabetes Research, Gentofte Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Empagliflozin
Placebo
Arm Description
One tablet 25 mg empagliflozin every morning for 14 days
One tablet placebo every morning for 14 days
Outcomes
Primary Outcome Measures
Urinary excretion of 8-oxo-7,8-dihydro-2'-deoxyguanosine (nmol/24h)
Urinary excretion of 8-oxo-7,8-dihydroguanosine (nmol/24h)
Secondary Outcome Measures
Plasma levels of malondialdehyde
Plasma levels of iron, ferritin, transferrin and transferrin saturation
Full Information
NCT ID
NCT02890745
First Posted
August 31, 2016
Last Updated
June 9, 2021
Sponsor
Henrik Enghusen Poulsen
Collaborators
University Hospital, Gentofte, Copenhagen, University of Copenhagen
1. Study Identification
Unique Protocol Identification Number
NCT02890745
Brief Title
The Effect Effect of Empagliflozin on Oxidative Stress in Patients With Type 2 Diabetes
Acronym
EMPOX
Official Title
EMPOX - A Randomised, Double-blinded, Placebo Controlled Study That Evaluates the Effect of Empagliflozin on Oxidative Stress in Patients With Type 2 Diabetes
Study Type
Interventional
2. Study Status
Record Verification Date
June 2021
Overall Recruitment Status
Completed
Study Start Date
November 2016 (Actual)
Primary Completion Date
January 22, 2020 (Actual)
Study Completion Date
January 22, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Henrik Enghusen Poulsen
Collaborators
University Hospital, Gentofte, Copenhagen, University of Copenhagen
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to investigate the effect of empagliflozin on oxidative stress in patients with type 2 diabetes. The association is examined by comparing the difference in oxidative modifications before and after 14 days treatment with 25 mg empagliflozin compared to placebo treatment. The study is randomised, double-blinded, and placebo controlled. Each treatment group consists of 17 males with type 2 diabetes. Oxidative modifications are measured by urinary excretion of 8-oxo-7,8-dihydro-2'-deoxyguanosine and 8-oxo-7,8-dihydroguanosine. A student t-test will be performed to compare the drug treatment with placebo. The results will be published in a peer-review journal.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
Keywords
Empagliflozin, Oxidative stress, Oxidative nucleic acid modifications, 8-oxo-7,8-dihydro-2'-deoxyguanosine, 8-oxo-7,8-dihydroguanosine
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
31 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Empagliflozin
Arm Type
Experimental
Arm Description
One tablet 25 mg empagliflozin every morning for 14 days
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
One tablet placebo every morning for 14 days
Intervention Type
Drug
Intervention Name(s)
Empagliflozin
Intervention Type
Drug
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
Urinary excretion of 8-oxo-7,8-dihydro-2'-deoxyguanosine (nmol/24h)
Time Frame
Change from baseline after fourteen days of intervention
Title
Urinary excretion of 8-oxo-7,8-dihydroguanosine (nmol/24h)
Time Frame
Change from baseline after fourteen days of intervention
Secondary Outcome Measure Information:
Title
Plasma levels of malondialdehyde
Time Frame
Change from baseline after fourteen days of intervention
Title
Plasma levels of iron, ferritin, transferrin and transferrin saturation
Time Frame
Measured at baseline and after intervention
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosed with type 2 diabetes
HbA1c: 6.5-9.0%
Capable of understanding oral- and written information
Caucasian
Exclusion Criteria:
Estimated glomerular filtration rate (eGFR) < 60 mL/hour/1.73 m2
Currently receiving insulin treatment
Coronary artery bypass grafting, percutaneous coronary intervention, acute coronary syndrome, stroke, lung embolism, deep vein thrombosis, or transitory cerebral ischemia within 6 months
Genital infection within 14 days
Plasma alanine aminotransferase ≥3 times upper normal limit
Treatment with sodium glucose cotransporter (SGLT) -2 inhibitor within 2 months
Hyperglycaemic symptoms
Psychiatric disorder
Intolerance to empagliflozin or other agents relevant to study
Non-compliant
Facility Information:
Facility Name
Center for Diabetes Research, Gentofte Hospital
City
Hellerup
ZIP/Postal Code
2900
Country
Denmark
12. IPD Sharing Statement
Citations:
PubMed Identifier
28490557
Citation
Larsen EL, Cejvanovic V, Kjaer LK, Vilsboll T, Knop FK, Rungby J, Poulsen HE. The effect of empagliflozin on oxidative nucleic acid modifications in patients with type 2 diabetes: protocol for a randomised, double-blinded, placebo-controlled trial. BMJ Open. 2017 May 9;7(5):e014728. doi: 10.1136/bmjopen-2016-014728.
Results Reference
derived
Learn more about this trial
The Effect Effect of Empagliflozin on Oxidative Stress in Patients With Type 2 Diabetes
We'll reach out to this number within 24 hrs